Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
University of Oklahoma
Study ID
NCT03476798
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Rucaparib — DRUG
    Rucaparib 600mg PO BID daily
  • Bevacizumab — DRUG
    Bevacizumab 15mg/kg IV on day 1 of each cycle

Study Details

This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these patients who survive progression-free for at least 6 months while receiving this drug combination.

Key Dates

Start date
Jun 29, 2018
Status verified
Feb 2024
Primary completion
May 12, 2020
Completion
Sep 29, 2023

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab + Rucaparib

Primary Outcome Measure

Proportion of Patients Who Are Progression-free at 6 Months [ Time Frame: 6 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
University of MinnesotaMinneapolisMinnesota55455-
Stephenson Cancer Center, University of Oklahoma Health Sciences CenterOklahoma CityOklahoma73117-
University of Virginia Cancer CenterCharlottesvilleVirginia22903-

Find similar trials in Minneapolis, MN

By condition
Cervical cancerEndometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of Minnesota· Minneapolis, MNStephenson Cancer Center, University of Oklahoma Health Sciences Center· Oklahoma City, OKUniversity of Virginia Cancer Center· Charlottesville, VA

Related Studies